From ZikV genome to vaccine: in silico approach for the epitope-based peptide vaccine against Zika virus envelope glycoprotein
From ZikV genome to vaccine: in silico approach for the epitope-based peptide vaccine against Zika virus envelope glycoprotein
复制标题
DOI：
10.1111/imm.12656
复制
发表时间：
2016-12-01
期刊：
影响因子：
6.4
通讯作者：
Ishrat, Romana
中科院分区：
文献类型：
--
作者：
Alam, Aftab;Ali, Shahnawaz;Ishrat, Romana
寨卡病毒（Zikv）已成为全球人类健康的潜在威胁。作为黄病毒科的一员，ZikV通过蚊子传播给人类。它与其他致病性媒介传播的黄病毒（包括登革热、西尼罗河病毒和日本脑炎病毒）有关，但在人类中产生相对温和的疾病。由于其流行病爆发和缺乏潜在的药物，需要改进疫苗/药物。计算技术将提供有关这种病毒的进一步信息。ZikV基因组的比较分析应该导致确定定义病毒家族的核心特征及其独特特性，而系统发育分析将显示进化关系并提供有关蛋白质祖先的线索。ZikV的包膜糖蛋白从蛋白质数据库获得，并且是参与细胞介导的免疫的T细胞和B细胞的最免疫原性表位，而B细胞主要负责体液免疫。我们主要集中在MHC I类潜在肽。YRIMLSVHG、VLIFLSTAV和MMLELDPPF、GLDFSDLYY分别是预测为CD 4（+）和CD 8（+）T细胞表位的最有效肽，而MMLELDPPF和GLDFSDLYY具有最高的pMHC-I免疫原性评分，并使用计算机对接技术进一步测试这些肽与HLA分子的相互作用，以验证结合裂缝表位。然而，这是一个介绍性的方法来设计针对ZikV的基于表位的肽疫苗;我们希望这个模型将有助于设计和预测新的候选疫苗。
Zika virus (ZikV) has emerged as a potential threat to human health worldwide. A member of the Flaviviridae, ZikV is transmitted to humans by mosquitoes. It is related to other pathogenic vector-borne flaviviruses including dengue, West Nile and Japanese encephalitis viruses, but produces a comparatively mild disease in humans. As a result of its epidemic outbreak and the lack of potential medication, there is a need for improved vaccine/drugs. Computational techniques will provide further information about this virus. Comparative analysis of ZikV genomes should lead to the identification of the core characteristics that define a virus family, as well as its unique properties, while phylogenetic analysis will show the evolutionary relationships and provide clues about the protein's ancestry. Envelope glycoprotein of ZikV was obtained from a protein database and the most immunogenic epitope for T cells and B cells involved in cell-mediated immunity, whereas B cells are primarily responsible for humoral immunity. We mainly focused on MHC class I potential peptides. YRIMLSVHG, VLIFLSTAV and MMLELDPPF, GLDFSDLYY are the most potent peptides predicted as epitopes for CD4(+) and CD8(+) T cells, respectively, whereas MMLELDPPF and GLDFSDLYY had the highest pMHC-I immunogenicity score and these are further tested for interaction against the HLA molecules, using in silico docking techniques to verify the binding cleft epitope. However, this is an introductory approach to design an epitope-based peptide vaccine against ZikV; we hope that this model will be helpful in designing and predicting novel vaccine candidates.